Form 4: IGM Biosciences CEO Sells Shares for Tax Obligations

IGM Biosciences CEO Mary Beth Harler sold 14,501 shares of common stock at a weighted average price of $1.2728 to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Mary Beth Harler, Chief Executive Officer and Director of IGM Biosciences, Inc. (IGMS), sold 14,501 shares of the company's common stock.
• The transaction occurred on July 23, 2025, and was executed as a pre-planned sale under a Rule 10b5-1 plan.
• The shares were sold at a weighted average price of $1.2728 per share, with individual trades ranging from $1.27 to $1.275.
• The purpose of this sale was to cover tax withholding obligations incurred in connection with the vesting of restricted stock units.
• Following this transaction, Mary Beth Harler directly beneficially owns 323,680 shares of IGM Biosciences common stock.

Sentiment

Score: 5

Explanation: The transaction is neutral. It is a routine sale to cover tax obligations from vested equity, which is a common practice and not indicative of a change in sentiment towards the company's prospects. The pre-planned nature (Rule 10b5-1) further supports its routine nature.

Positives

• The sale was conducted under a Rule 10b5-1 plan, indicating a pre-arranged and systematic approach to managing equity compensation, which can reduce concerns about discretionary insider selling.

Negatives

• The transaction resulted in a reduction of 14,501 shares in the direct beneficial ownership of a key executive.

Future Outlook

No forward-looking statements or guidance are provided in this filing.

Industry Context

This is a routine insider transaction related to equity compensation, a common practice across all industries, including biotechnology, where executive compensation frequently includes restricted stock units. It does not reflect broader industry trends or competitive dynamics.

Stakeholder Impact

• Shareholders: A minor reduction in insider ownership, but the stated reason (tax withholding) mitigates concerns about management confidence in the company's future.

Key Dates

Recommendation

The sale of shares by the CEO is specifically for tax withholding obligations related to vested restricted stock units and was executed under a pre-planned Rule 10b5-1 arrangement. This type of transaction is routine and does not typically signal a change in management's confidence or the company's fundamentals. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

IGM Biosciences, IGMS, SEC Form 4, Insider Trading, Stock Sale, CEO, Restricted Stock Units, Tax Withholding, Rule 10b5-1, Biotechnology